Medication-Related Osteonecrosis of the Jaw (MRONJ): Prevention and Management

Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse event characterized by exposed necrotic bone in the maxillofacial region that persists for more than eight weeks in patients with current or previous antiresorptive or antiangiogenic therapy and no history of head and neck radiation therapy. First reported in 2003, MRONJ has become one of the most clinically challenging conditions in dentistry and oral and maxillofacial surgery. The rising use of antiresorptive agents for osteoporosis and malignancy, combined with increasing survival rates in cancer patients, ensures that dental practitioners across all specialties will encounter at-risk patients with growing frequency.

Epidemiology and Risk Assessment

The incidence of MRONJ varies dramatically depending on the indication, agent, route of administration, and duration of therapy. Among osteoporosis patients receiving oral bisphosphonates, the incidence is estimated at 0.01% to 0.1% per year of exposure, rising to approximately 0.2% after four years of use. For cancer patients receiving high-dose intravenous bisphosphonates or denosumab, incidence rates range from 1% to 15%, with cumulative incidence increasing with duration of therapy.

Dentoalveolar surgery, particularly tooth extraction, is the most common precipitating event, implicated in 60% to 80% of MRONJ cases. Other local risk factors include periodontal disease, periapical pathology, ill-fitting dentures causing mucosal trauma, and concurrent oral inflammatory conditions. Systemic risk factors include corticosteroid use, diabetes mellitus, smoking, chemotherapy, and antiangiogenic agents such as bevacizumab and sunitinib. Genetic polymorphisms in the farnesyl pyrophosphate synthase (FDPS) gene and cytochrome P450 2C8 (CYP2C8) have been associated with altered susceptibility, suggesting a pharmacogenomic component to MRONJ risk.

Pathophysiology: The Multifactorial Model

MRONJ pathophysiology is complex and incompletely understood. The prevailing model is multifactorial, involving suppressed bone remodeling, inhibition of angiogenesis, oral mucosal toxicity, altered immunity, and microbial infection.

Bone Remodeling Suppression

Bisphosphonates inhibit osteoclast-mediated bone resorption through two mechanisms. Nitrogen-containing bisphosphonates (alendronate, risedronate, ibandronate, pamidronate, zoledronate) inhibit farnesyl pyrophosphate synthase in the mevalonate pathway, disrupting protein prenylation and inducing osteoclast apoptosis. Non-nitrogenous bisphosphonates incorporate into non-hydrolyzable ATP analogs that accumulate intracellularly and cause osteoclast death. Denosumab, a fully human monoclonal antibody against RANKL, inhibits osteoclast differentiation, activation, and survival. The net effect is profoundly suppressed bone turnover, with histomorphometric studies demonstrating bone formation rates near zero in bisphosphonate-treated patients.

The jawbones are particularly vulnerable due to their high baseline remodeling rate—ten times that of the iliac crest—driven by continuous mechanical loading from mastication and the constant microbial challenge from the oral environment. Microcracks that accumulate under normal function cannot be repaired in the absence of osteoclast activity, leading to bone fatigue and necrosis.

Angiogenesis Inhibition

Bisphosphonates inhibit endothelial cell proliferation and tube formation in vitro and reduce circulating endothelial progenitor cells in vivo. Zoledronate has been shown to decrease VEGF levels and microvessel density in animal models. This antiangiogenic effect compromises the healing capacity of mucosal and osseous tissues following injury, creating a persistent wound environment conducive to bacterial colonization.

Oral Mucosal Toxicity and Infection

Bisphosphonates accumulate preferentially in bone with high turnover, reaching concentrations that are directly toxic to overlying oral epithelium. In vitro studies demonstrate bisphosphonate-induced keratinocyte apoptosis and inhibition of oral fibroblast proliferation. Mucosal breakdown exposes underlying bone to the complex oral microbiome. Actinomyces species are consistently cultured from MRONJ lesions, and biofilm formation on necrotic bone perpetuates the inflammatory cycle. Animal models confirm that the combination of bisphosphonate exposure, dental intervention, and bacterial presence is necessary to reliably induce osteonecrosis, supporting the "perfect storm" hypothesis.

Staging and Clinical Presentation

The American Association of Oral and Maxillofacial Surgeons (AAOMS) staging system, most recently updated in 2022, classifies MRONJ into four stages:

Stage 0: No clinical evidence of exposed necrotic bone, but nonspecific symptoms and radiographic findings are present. Patients may report deep jaw pain, sinus pain, altered neurosensory function, or tooth mobility not explained by periodontal disease. Radiographic features include alveolar bone loss or resorption not attributable to chronic periodontitis, changes to trabecular pattern (dense woven bone and persistence of unremodeled extraction sockets), and regions of osteosclerosis extending to the alveolar bone.

Stage 1: Exposed and necrotic bone or fistulae that probes to bone in asymptomatic patients without evidence of infection. Radiographs show the characteristic features described for Stage 0, localized to the alveolar bone region.

Stage 2: Exposed and necrotic bone or fistulae that probes to bone, associated with pain, erythema, and evidence of infection (with or without purulent drainage). Radiographic findings are as above but may extend to the inferior border of the mandible or involve the maxillary sinus floor.

Stage 3: Exposed and necrotic bone or fistulae that probes to bone with pain, infection, and at least one of the following: pathologic fracture, extraoral fistula, oral-antral or oral-nasal communication, or extension to the inferior border of the mandible or sinus floor.

Prevention: The Dental Practitioner's Central Role

Prevention is the most effective strategy for MRONJ and represents the greatest opportunity for dental practitioners to improve patient outcomes. The cornerstone of prevention is comprehensive dental evaluation and treatment optimization prior to initiation of antiresorptive therapy.

Pretreatment Dental Clearance

All patients scheduled to begin bisphosphonate or denosumab therapy for malignancy should undergo a thorough dental examination with panoramic radiography and selective periapical films. The goal is to identify and eliminate potential sources of infection and avoid the need for future dentoalveolar surgery. Treatment priorities include extraction of non-restorable teeth, completion of endodontic therapy, periodontal debridement and stabilization, removal of tori or exostoses that may be susceptible to trauma, and adjustment of removable prostheses to eliminate pressure points.

A minimum healing period of 14 to 21 days should elapse between completion of dental treatment and initiation of antiresorptive therapy to allow for mucosal coverage of extraction sockets. For oncology patients in whom treatment cannot be delayed, the risk-benefit discussion must include the oncologist, and the dental treatment plan should be accelerated accordingly.

Ongoing Maintenance and Monitoring

Patients on antiresorptive therapy require more frequent recall intervals—every 3 to 4 months rather than the standard 6-month interval. Maintenance visits should emphasize meticulous oral hygiene instruction, professional prophylaxis, and careful inspection of the oral mucosa for early signs of breakdown. Denture wearers should be counseled to remove prostheses at night and report any areas of soreness or ulceration immediately.

Elective dentoalveolar surgery should be avoided whenever possible. Endodontic treatment is preferred over extraction for restorable teeth, and crown lengthening should be considered cautiously. When extraction is unavoidable, the least traumatic technique should be employed, with primary closure if achievable without tension. Perioperative antimicrobial rinses (0.12% chlorhexidine) and systemic antibiotics (typically penicillin V or doxycycline for at least 7 days postoperatively) are recommended.

Drug Holidays

The concept of a "drug holiday"—temporarily discontinuing antiresorptive therapy to reduce MRONJ risk—remains controversial and should only be considered in consultation with the prescribing physician. For oral bisphosphonates used in osteoporosis, a drug holiday of 2 to 3 months prior to elective oral surgery with resumption after complete mucosal healing has been proposed, though evidence supporting this practice is limited to expert opinion and case series. For intravenous bisphosphonates and denosumab, whose skeletal half-life is measured in years, a drug holiday of months is unlikely to meaningfully alter bone turnover, and the risk of interrupting cancer treatment must be weighed carefully.

Management Strategies by Stage

Non-Surgical Management (Stages 0-1)

The initial management of MRONJ is conservative. Antimicrobial mouth rinses (0.12% chlorhexidine gluconate twice daily) reduce bacterial colonization of exposed bone surfaces. Systemic antibiotics are reserved for symptomatic patients (Stage 2 and above), with penicillin V 500 mg four times daily or doxycycline 100 mg daily as first-line agents, typically combined with metronidazole for anaerobic coverage. Pain is managed with NSAIDs and, when necessary, opioid analgesics under appropriate supervision.

Sequestrectomy of mobile bone fragments can be performed as they naturally demarcate, avoiding removal of firmly attached bone that may serve as a scaffold for mucosal coverage. The role of hyperbaric oxygen therapy remains undefined, with conflicting evidence from small case series. Pentoxifylline and tocopherol (vitamin E) have shown promise in small studies for refractory osteoradionecrosis but data for MRONJ are limited.

Surgical Management (Stages 2-3)

Surgical intervention is indicated for patients with persistent symptoms despite conservative measures, progressive bone involvement, or Stage 3 disease. The surgical approach has evolved from conservative debridement to more aggressive resection with the goal of achieving margins that bleed—indicating viable bone. Preoperative cone-beam CT or CT imaging delineates the extent of bony involvement and guides surgical planning.

Marginal or segmental resection is performed with primary closure using tension-free mucoperiosteal flaps. Fluorescence-guided surgery using tetracycline labeling has been explored to improve discrimination between necrotic and viable bone intraoperatively. The use of platelet-rich fibrin (PRF) membranes has gained popularity as a biological dressing that delivers concentrated growth factors to the surgical site and may promote soft tissue healing.

Postoperative complications include wound dehiscence (15-25%), persistent infection, and recurrence at the same or contralateral site. Long-term outcomes data suggest surgical cure rates of 60% to 90%, with higher success rates reported for mandibular versus maxillary lesions and for patients with limited versus extensive disease.

Special Considerations

Antiangiogenic Agents

Antiangiogenic tyrosine kinase inhibitors (sunitinib, sorafenib) and monoclonal antibodies (bevacizumab) have been associated with MRONJ, both as monotherapy and in combination with antiresorptives. The incidence appears lower than for bisphosphonates alone, but the clinical presentation is similar. Management principles are identical, with the important caveat that these agents may impair soft tissue healing to a greater degree than bisphosphonates, influencing surgical decisions.

Implant Therapy in At-Risk Patients

Dental implant placement in patients on antiresorptive therapy remains controversial. Systematic reviews report implant survival rates of 90% to 95% in patients on oral bisphosphonates for osteoporosis, comparable to the general population. However, cases of implant-related MRONJ have been reported. For oncology patients on high-dose intravenous therapy, implant placement is generally considered contraindicated. A detailed informed consent discussion documenting the risks, benefits, and alternatives—including the possibility of MRONJ—is essential.

Conclusion

MRONJ remains a significant clinical challenge at the intersection of dentistry, oncology, and rheumatology. Prevention through pretreatment dental clearance and meticulous ongoing maintenance represents the most effective strategy for reducing disease burden. When MRONJ occurs, a multidisciplinary approach involving the dental practitioner, oral and maxillofacial surgeon, and prescribing physician ensures coordinated care that balances oral health needs with the management of underlying systemic disease. Ongoing research into the molecular pathogenesis of MRONJ, including genetic susceptibility factors and the oral microbiome's role, promises to refine risk stratification and therapeutic approaches in the coming decade.